Equities

Nordhealth AS

Nordhealth AS

Actions
Health CareHealth Care Providers
  • Price (NOK)31.90
  • Today's Change0.300 / 0.95%
  • Shares traded728.00
  • 1 Year change+28.11%
  • Beta--
Data delayed at least 15 minutes, as of Jul 03 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nordhealth AS is a Norway-based cloud-based healthcare Software-as-a-Service business. The Company's flagship products are Provet Cloud and Diarium, both cloud-based Practice Management Software for veterinarians and therapists, respectively. The Group serves over 7,000 clinics and hospitals located in over 25 countries. Nordhealth's mission is to build software that empowers healthcare professionals to improve patient care, increase efficiency and expand their business.

  • Revenue in NOK (TTM)422.07m
  • Net income in NOK-127.60m
  • Incorporated2021
  • Employees395.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mentice AB255.63m-26.13m740.90m128.00--5.431,796.062.90-1.01-1.0110.035.300.84351.973.882,082,557.00-8.62-7.69-17.02-13.0787.5783.67-10.22-10.000.8586--0.0553--25.5411.7490.81---10.83--
Omda AS416.87m88.33m752.59m291.008.438.614.751.814.274.2720.444.180.5534168.9410.731,432,536.0012.70-4.9216.78-6.3792.5690.2222.96-9.831.252.580.8487--12.3019.83179.30---3.93--
Senzime AB (publ)40.83m-132.08m763.94m52.00--2.56--18.71-1.30-1.300.39022.950.10451.345.80---33.80-35.69-35.58-38.0026.75-20.59-323.45-558.685.85--0.0308--154.7761.90-1.09---3.69--
Gentian Diagnostics ASA142.22m-5.83m886.79m58.00--5.86247.716.24-0.3783-0.37839.229.820.76461.856.352,452,035.00-3.14-10.76-3.58-11.8650.8441.46-4.10-26.994.14--0.0555--32.9827.6354.92---4.92--
OssDsign AB118.44m-119.12m913.80m48.00--4.05--7.72-1.51-1.511.402.300.39073.606.622,452,500.00-39.29-37.92-43.39-43.5677.1568.10-100.57-203.065.18-36.900.013--96.8453.26-31.30---56.16--
Nightingale Health Oyj41.61m-205.66m925.64m81.00--1.36--22.24-0.2979-0.29790.06031.500.03441.603.8744,560.98-17.02-14.20-18.12-15.6975.8183.57-494.25-408.5014.15--0.0378--80.8019.05-12.38------
Paxman AB (publ)227.81m24.12m983.24m94.0040.857.1822.964.321.261.2611.897.161.282.666.462,488,099.0013.59-5.0818.38-7.7669.4769.3810.59-5.071.76--0.1122--43.9929.35180.69--6.26--
Integrum AB104.76m4.20m1.08bn36.00261.097.06169.8410.340.21990.21995.558.130.63070.59193.802,892,222.002.530.76122.800.881887.6583.874.011.283.32--0.043--40.1935.91212.14--127.10--
SyntheticMR AB (publ)91.41m15.77m1.16bn38.0072.829.6152.2512.710.38040.38042.212.880.6719--1.582,455,541.0011.597.1913.878.8573.9469.7017.259.08----0.008321.5030.6713.0570.34-7.3327.30--
Optomed Oyj170.24m-49.80m1.31bn114.00--5.44--7.72-0.2575-0.25750.88721.080.51991.703.94131,131.60-15.21-12.95-18.59-15.9066.7665.69-29.25-27.841.72-12.960.1894--3.003.4718.84--7.26--
BioPorto A/S49.44m-82.18m1.41bn27.00--19.57--28.53-0.1501-0.15010.09030.10990.41323.667.331,044,452.00-68.68-71.10-100.20-96.5568.0863.38-166.23-239.222.36--0.1354--6.873.5425.81---51.56--
Nordhealth As422.07m-127.60m1.43bn395.00--2.64--3.39-1.62-1.625.3412.000.3561--8.251,068,542.00-10.76---12.25--85.96---30.23------0.00--18.60--21.96------
C Rad AB461.03m48.52m1.44bn89.0030.485.0624.933.131.431.4313.578.611.204.903.055,266,839.0012.695.0917.967.0245.1443.1210.614.862.43--0.00580.0040.9217.44375.0510.8933.69--
ADDvise Group AB (publ)1.48bn111.48m1.47bn620.0026.603.726.530.99260.58640.58647.844.200.55066.735.522,365,224.004.143.725.174.7747.6348.957.515.891.092.990.66080.940544.3038.6227.62--30.35--
Genovis AB127.79m30.87m1.78bn36.0057.518.6042.5713.890.46860.46861.943.130.5084----3,432,784.0012.2818.5613.3721.4566.0965.5124.1523.88----0.27690.0054.5435.56449.56--47.59--
Stille AB364.38m35.80m1.94bn142.0035.832.9936.225.336.006.0060.2071.840.53641.777.183,416,557.005.277.036.358.1946.7643.939.829.850.98797.170.0021.9819.7016.78-2.485.3423.62--
Data as of Jul 03 2024. Currency figures normalised to Nordhealth AS's reporting currency: Norwegian Krone NOK

Institutional shareholders

37.28%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 31 Mar 20245.12m11.33%
Fj�rde AP-fondenas of 31 Dec 20233.27m7.24%
Pareto Asset Management ASas of 30 Jun 20232.90m6.42%
Herald Investment Management Ltd.as of 31 Dec 20231.36m3.01%
Capital Research & Management Co. (Global Investors)as of 31 Mar 20241.28m2.83%
Aktia Bank Plc (Investment Management)as of 31 May 2024925.00k2.05%
OP Asset Management Ltd.as of 31 Dec 2023680.31k1.51%
Laiqon AG (Investment Management)as of 31 Jan 2024610.70k1.35%
Schroder Investment Management Ltd.as of 31 Dec 2023501.00k1.11%
Barius Capital Management GmbHas of 31 Mar 2024200.45k0.44%
More ▼
Data from 31 Jan 2024 - 31 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.